<DOC>
	<DOCNO>NCT02227212</DOCNO>
	<brief_summary>Primary Objective : To demonstrate ease use U300 pen injector pen-naïve insulin-naïve type 2 diabetes mellitus ( T2DM ) patient 4-week once-daily dose regimen HOE901-U300 . Secondary Objectives : To assess 4-week once-daily dose regimen HOE901-U300 pen-naïve insulin-naïve T2DM patient . The safety usability U300 pen injector . The glycemic control U300 pen injector . The safety HOE901-U300 .</brief_summary>
	<brief_title>Ease Use Safety New U300 Pen Injector Insulin-Naïve Patients With T2DM</brief_title>
	<detailed_description>The total study duration participant approximately 10 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients T2DM inadequately control noninsulin , noninjectable antihyperglycemic drug ( ) Investigator/treating physician decide basal insulin appropriate . Signed write informed consent . Exclusion criterion : Glycated hemoglobin A1c ( HbA1c ) &lt; 7.0 % ( &lt; 53 mmol/mol ) &gt; 11 % ( 97 mmol/mol ) screening . Age &lt; 18 year time screen . Body Mass Index ( BMI ) &gt; 40 kg/m2 . Diabetes T2DM . History T2DM less 1 year screening . Less 6 month antihyperglycemic treatment screening . Initiation new glucoselowering medication and/or weight loss drug last 3 month screen visit . Previous treatment Glucagon Like Peptide1 ( GLP1 ) agonist . Patients receive noninsulin antihyperglycemic drug approve combination insulin accord local labeling/local treatment guideline and/or sulfonylurea glinides . Current previous insulin use except maximum 8 consecutive day total 14 day ( eg , acute illness , surgery ) last year prior screen . Any contraindication insulin glargine ( Lantus ) accord National Product label excipients . Any contraindication mandatory background noninsulin antihyperglycemic medication accord respective National Product labeling . Latest eye examination ophthalmologist &gt; 12 month prior inclusion . More one episode severe hypoglycemia seizure , coma require assistance another person past 6 month . Unstable proliferative diabetic retinopathy rapidly progressive diabetic retinopathy macular edema likely require treatment ( eg , laser , surgical treatment injectable drug ) study period . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>